Projects per year
Personal profile
Expertise
Elke De Bruyne completed a masters degree in Biomedical Sciences at the Vrije Universiteit Brussel (VUB). After obtaining her masters degree, she started her scientific career as a PhD student at the Department of Hematology and Immunology (HEIM) at VUB (Prof. Ben Van Camp and Prof. Karin Vanderkerken). The topic of her PhD was the role of endothelial cells in bone marrow microenvironment-induced modulation of gene-expression of multiple myeloma cells. After obtaining a post-doctoral fellowship of the FWO-Vlaanderen, she remained member of the HEIM lab and became principal investigator for the study on epigenetics in MM focusing on the epigenetic regulation of malignant plasma cells within the supportive bone marrow and the therapeutic and diagnostic potential of broad acting epigenetic modulating agents (e.g. pan-HDACi and DNMTi) in MM.
Currently, she holds a faculty position and supervises a growing team of researchers focussing on epigenetic modifiers and their role in drug resistance in MM and cancer in general. Besides this topic, she is also involved in research projects aiming to explore the therapeutic potential of targeting mitotic exit in combination with standard of care agents for high grade B cell malignancies. Since 2015, she is a member of the scientific committee ‘KomOpTegenKanker’ (expert panel). In 2017, she also became a member of the OPINNO steering committee (flanders.bio)
Fingerprint
Dive into the research topics where Elke De Bruyne is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
ANI302: ExoRAS: a novel, exosome-based K/N-RAS-targeting tool to overcome drug resistance in multiple myeloma
1/10/21 → 30/09/25
Project: Fundamental
-
OZR3740: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - KU Leuven, DE COSTER Michiel
22/10/20 → 21/10/24
Project: Fundamental
-
OZR3588: Financiering FWO hercules: ERA platform: Extended RNA Analysis platform - version 2.0
Rooman, I., Bouwens, L., Heimberg, H., Neyns, B., Vranken, W., Vanhaecke, T., Massie, A., van Grunsven, L., De Bruyne, E., De Bundel, D., Forsyth, R., Breckpot, K., Van Dooren, S., De Kock, J., Njemini, R. & Laoui, D.
1/05/20 → 30/04/24
Project: Fundamental
-
OZRSRF34: Specific targeting of epiplayers driving drug resistance in cancer: paving the way to personalized treatment? - SRF mandate
1/11/19 → 31/10/24
Project: Fundamental
Research output
-
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
Nylund, P., Atienza Párraga, A., Haglöf, J., De Bruyne, E., Menu, E., Garrido-Zabala, B., Ma, A., Jin, J., Öberg, F., Vanderkerken, K., Kalushkova, A. & Jernberg-Wiklund, H., 12 Feb 2021, In : Cell & Death Disease. 12, 2, 16 p., 167.Research output: Contribution to journal › Article
Open AccessFile2 Citations (Scopus)49 Downloads (Pure) -
G9a/GLP-targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor mediated cell death
Muylaert, C., De Bruyne, E., Maes, K., Vlummens, P., De Smedt, E., Moreaux, J. & Devin, J., 24 Feb 2021, In : Blood Advances. 5, 9, p. 2325-2338 14 p.Research output: Contribution to journal › Article
Open Access -
Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma
Herviou, L., Ovejero, S., Izard, F., Karmous-Gadacha, O., Gourzones, C., Bellanger, C., De Smedt, E., Ma, A., Vincent, L., Cartron, G., Jin, J., De Bruyne, E., Grimaud, C., Julien, E. & Moreaux, J., 16 Sep 2021, In : Clinical Epigenetics. 13, 1, 18 p., 174.Research output: Contribution to journal › Article
Open Access -
AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers
Vlummens, P., De Beule, N., Faict, S., Oudaert, I., Maes, K., De Bruyne, E., Menu, E., Vanderkerken, K. & De Veirman, K., 14 Feb 2020, In : Belgian Journal of Hematology. 11, O2, p. 9-9 1 p., 11.Research output: Contribution to journal › Meeting abstract (Journal)
-
Kinome expression profiling to target new therapeutic avenues in multiple myeloma
de Boussac, H., Bruyer, A., Jourdan, M., Maes, A., Robert, N., Gourzones, C., Vincent, L., Seckinger, A., Cartron, G., Hose, D., De Bruyne, E., Kassambara, A., Pasero, P. & Moreaux, J., 1 Mar 2020, In : Haematologica. 105, 3, p. 784-795 12 p.Research output: Contribution to journal › Article
Open AccessFile10 Citations (Scopus)3 Downloads (Pure)
Prizes
-
Abstract Achievement Award
Elke De Bruyne (Recipient), 7 Dec 2012
Prize: Prize (including medals and awards)
-
Brian D. Novis Junior Research Award
Elke De Bruyne (Recipient), 1 Jan 2014
Prize: Prize (including medals and awards)
-
Fund Catherina Weekers- King Baudouin Foundation
Elke De Bruyne (Recipient), 26 Nov 2009
Prize: Prize (including medals and awards)
-
Activities
-
Research Foundation - Flanders (External organisation)
Elke De Bruyne (Reviewer)2020 → …Activity: Membership › Membership of peer-review panel or committee
-
European Hematology Association (External organisation)
Elke De Bruyne (Member)2019 → …Activity: Membership › Membership of external research organisation
-
G9a/GLP targeting blocks myeloma cell growth and survival by suppressing mTOR- and Myc-signaling
Elke De Bruyne (Speaker)13 Jun 2019Activity: Talk or presentation › Talk or presentation at a conference
-
MCL1 Inhibitors in Multiple Myeloma
Kim De Veirman (Contributor), Karin Vanderkerken (Speaker), Elke De Bruyne (Contributor), Eline Menu (Contributor)13 Nov 2019Activity: Talk or presentation › Talk or presentation at a conference
-
JoPCaRS for Joined Preclinical Cancer Research Seminars
Cleo Goyvaerts (Chair), Elke De Bruyne (Chair)2018 → …Activity: Participating in or organising an event › Participating in or organizing an event at an external academic organisation
Thesis
-
Epigenetische onderdrukking van het pro-apoptotisch gen Bim in multipel myeloom
Author: Rijpers, E., Vanderkerken, K. & De Bruyne, E., 1 Jun 2008Supervisor: Vanderkerken, K. (Promotor) & De Bruyne, E. (Co-promotor)
Student thesis: Master's Thesis
-
Etude des effects in vitro et in vivo de la décitabine dans let myélome muliple
Author: Gauthier, J., De Bruyne, E. & Vanderkerken, K., 25 Jun 2012Supervisor: De Bruyne, E. (Promotor) & Vanderkerken, K. (Co-promotor)
Student thesis: Master's Thesis
-
Exploring the therapeutic potential of targeting mitotic exit in combination with standard of care agents in high grade B cell malignancies.
Author: Maes, A., De Bruyne, E., Vanderkerken, K., Pellat-Deceunynck, C., De Keersmaecker, K., De Grève, J., Gutierrez, G. J. & Van Riet, I., 18 Nov 2019Supervisor: De Bruyne, E. (Promotor), Vanderkerken, K. (Promotor), Pellat-Deceunynck, C. (External person) (Jury), De Keersmaecker, K. (External person) (Jury), De Grève, J. (Jury), Gutierrez Gonzalez, G. (Jury) & Van Riet, I. (External person) (Jury)
Student thesis: Doctoral Thesis
-
Role of endothelial cells in bone marrow microenvironment-induced modulation of the gene expression of multiple myeloma cells’
Author: De Bruyne, E., Vanderkerken, K., Van Riet, I., De Grève, J., Van Ginderachter, J., van Grunsven, L. A., Croucher, P. I., Offner, F. & Van de Velde, A., 28 Jan 2010Supervisor: Vanderkerken, K. (Promotor), Van Riet, I. (Co-promotor), De Greve, J. (Jury), Van Ginderachter, J. (Jury), Van Grunsven, L. A. (Jury), Croucher, P. I. (External person) (Jury), Offner, F. (External person) (Jury) & Van De Velde, A. (External person) (Jury)
Student thesis: Doctoral Thesis
-
The anti-myeloma activity of pan-Pim kinase inhibitors
Author: Theuns, R. & De Bruyne, E., 19 Jun 2015Supervisor: De Bruyne, E. (Promotor)
Student thesis: Master's Thesis